IP Library Granted Patent US 7,241,899
Granted Patent B2
US 7,241,899 · App. 10/805,724 · Granted Jul 10, 2007

Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,241,899
App. No.
10/805,724
Granted
Jul 10, 2007
Kind
B2
Abstract

The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification.

Claims (33)

1. A crystalline solvate comprising: a toluene-containing epothilone B clathrate.

2. The crystalline solvate according to claim 1 characterized by unit cell parameters approximately equal to the following:

Cell dimensions:

a = 11.853(1) Å

b = 10.613(2) Å

c = 14.328(2) Å

Volume = 1659(1) Å 3

Space group

P2 1

Molecules/unit cell

4

Density (calculated) (g/cm 3 )

1.201

wherein the crystalline solvate is at a temperature of about −33° C.

3. The crystalline solvate according to claim 1 wherein said crystalline solvate is characterized by peaks in a powder x-diffraction pattern at a value of two theta (CuKα λ=1.5418 Å) of about 13.4, 20.2, 22.0, and 24.9, at a temperature of 23° C.

4. The crystalline solvate according to claim 3 wherein said crystalline solvate is further characterized by peaks in a powder x-ray diffraction pattern at a value of two theta (CuKα λ=1.5418 Å)of about 6.7, 8.2, 11.7, 12.7, 15.0, 15.8, 16.7, 18.5, 20.9, 21.5, 24.3, 26.3, 28.5, and 30.1, at a temperature of 23° C.

5. The crystalline solvate according to claim 1 , which comprises about one molecule of toluene per one molecule of the epothilone B.

6. The crystalline solvate according to claim 5 characterized by unit cell parameters approximately equal to the following:

Cell dimensions:

a = 11.853(1) Å

b = 10.613(2) Å

c = 14.328(2) Å

Volume = 1659(1) Å 3

Space group

P2 1

Molecules/unit cell

4

Density (calculated) (g/cm 3 )

1.201

wherein the crystalline solvate is at a temperature of about −33° C.

7. The crystalline solvate according to claim 5 wherein said crystalline solvate is characterized by peaks in a powder x-diffraction pattern at a value of two theta (CuKα λ=1.5418 Å) of about 13.4, 20.2, 22.0, and 24.9, at a temperature of 23° C.

8. The crystalline solvate according to claim 7 wherein said crystalline solvate is further characterized by peaks in a powder x-ray diffraction pattern at a value of two theta (CuKα λ=1.5418 Å) of about 6.7, 8.2, 11.7, 12.7,15.0, 15.8, 16.7, 18.5, 20.9, 21.5, 24.3, 26.3, 28.5, and 30.1, at a temperature of 23° C.

9. The crystalline solvate according to claim 1 characterized by: fractional atomic coordinates substantially as listed in Table 5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2015
From: BRISTOL-MYERS SQUIBB COMPANY
To: R-PHARM US OPERATING LLC
Reel/Frame 036585/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2004
From: GOUGOUTAS, JACK Z.; DIMARCO, JOHN
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 014525/0426 →